Type 2 Diabetes and Cognitive Compromise. Potential Roles of Diabetes-Related Therapies.

Endocrinology and Metabolism Clinics of North America

Volumn 42, Issue 3, 2013, Pages 489-501

  Kravitz, Efrat ^a   Schmeidler, James ^b   Schnaider Beeri, Michal ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Cognitive decline; Dementia; Insulin; Insulin resistance; Oral hypoglycemics; Type 2 diabetes

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; HUMAN; INSULIN SENSITIVITY; LOW DRUG DOSE; MENTAL DETERIORATION; NEUROPATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYMPTOMATOLOGY;

ALZHEIMER DISEASE; COGNITIVE DECLINE; DEMENTIA; INSULIN; INSULIN RESISTANCE; ORAL HYPOGLYCEMICS; TYPE 2 DIABETES;

AGED; DEMENTIA; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84883516249     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2013.05.009     Document Type: Review

References (104)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. 2011. Available at: Accessed March 21, 2013. http://www.cdc.gov/diabetes/pubs/factsheet11.htm.
2. Alzheimer's Association 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013, 9(2):208-245.
3. Cukierman T., Gerstein H.C., Williamson J.D. Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 2005, 48(12):2460-2469.
4. Xu W., Qiu C., Winblad B., et al. The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 2007, 56(1):211-216.
5. Janson J., Laedtke T., Parisi J.E., et al. Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 2004, 53(2):474-481.
6. Daviglus M.L., Bell C.C., Berrettini W., et al. National Institutes of Health State-of-the-Science Conference statement: preventing Alzheimer disease and cognitive decline. Ann Intern Med 2010, 153(3):176-181.
7. de la Monte S.M., Tong M., Lester-Coll N., et al. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. JAlzheimers Dis 2006, 10(1):89-109.
8. Ravona-Springer R., Luo X., Schmeidler J., et al. Diabetes is associated with increased rate of cognitive decline in questionably demented elderly. Dement Geriatr Cogn Disord 2010, 29(1):68-74.
9. Arvanitakis Z., Wilson R.S., Bienias J.L., et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004, 61(5):661-666.
10. Gilmour H. Cognitive performance of Canadian seniors. Health Rep 2011, 22(2):27-31.
11. Gregg E.W., Yaffe K., Cauley J.A., et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000, 160(2):174-180.
12. Hassing L.B., Grant M.D., Hofer S.M., et al. Type 2 diabetes mellitus contributes to cognitive decline in old age: a longitudinal population-based study. JInt Neuropsychol Soc 2004, 10(4):599-607.
13. Hassing L.B., Hofer S.M., Nilsson S.E., et al. Comorbid type 2 diabetes mellitus and hypertension exacerbates cognitive decline: evidence from a longitudinal study. Age Ageing 2004, 33(4):355-361.
14. Knopman D., Boland L.L., Mosley T., et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001, 56(1):42-48.
15. Logroscino G., Kang J.H., Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ 2004, 328(7439):548.
16. Nandipati S., Luo X., Schimming C., et al. Cognition in non-demented diabetic older adults. Curr Aging Sci 2012, 5(2):131-135.
17. Ravona-Springer R., Moshier E., Schmeidler J., et al. Changes in glycemic control are associated with changes in cognition in non-diabetic elderly. JAlzheimers Dis 2012, 30(2):299-309.
18. van den Berg E., de Craen A.J., Biessels G.J., et al. The impact of diabetes mellitus on cognitive decline in the oldest of the old: a prospective population-based study. Diabetologia 2006, 49(9):2015-2023.
19. Sanz C., Andrieu S., Sinclair A., et al. Diabetes is associated with a slower rateof cognitive decline in Alzheimer disease. Neurology 2009, 73(17):1359-1366.
20. Sanz C.M., Hanaire H., Vellas B.J., et al. Diabetes mellitus as a modulator of functional impairment and decline in Alzheimer's disease. The Real.FR cohort. Diabet Med 2012, 29(4):541-548.
21. Petersen R.C., Smith G.E., Waring S.C., et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999, 56(3):303-308.
22. Luchsinger J.A., Reitz C., Patel B., et al. Relation of diabetes to mild cognitive impairment. Arch Neurol 2007, 64(4):570-575.
23. Solfrizzi V., Panza F., Colacicco A.M., et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology 2004, 63(10):1882-1891.
24. Yaffe K., Blackwell T., Kanaya A.M., et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004, 63(4):658-663.
25. Roberts R.O., Geda Y.E., Knopman D.S., et al. Association of duration and severity of diabetes mellitus with mild cognitive impairment. Arch Neurol 2008, 65(8):1066-1073.
26. American Psychiatric Association Diagnostic and statistical manual of mental disorders, fourth edition, text revision (DSM-IV-TR) 2000, American Psychiatric Press, Washington, DC.
27. Schnaider Beeri M., Goldbourt U., Silverman J.M., et al. Diabetes mellitus in midlife and the risk of dementia three decades later. Neurology 2004, 63(10):1902-1907.
28. Leibson C.L., Rocca W.A., Hanson V.A., et al. The risk of dementia among persons with diabetes mellitus: a population-based cohort study. Ann N Y Acad Sci 1997, 826:422-427.
29. Ott A., Stolk R.P., van Harskamp F., et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999, 53(9):1937-1942.
30. Peila R., Rodriguez B.L., Launer L.J. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia Aging Study. Diabetes 2002, 51(4):1256-1262.
31. Whitmer R.A., Sidney S., Selby J., et al. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005, 64(2):277-281.
32. Xu W.L., Qiu C.X., Wahlin A., et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 2004, 63(7):1181-1186.
33. Dubois B., Feldman H.H., Jacova C., et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007, 6(8):734-746.
34. O'Brien J.T. Vascular cognitive impairment. Am J Geriatr Psychiatry 2006, 14(9):724-733.
35. Wang K.C., Woung L.C., Tsai M.T., et al. Risk of Alzheimer's disease in relation to diabetes: a population-based cohort study. Neuroepidemiology 2012, 38(4):237-244.
36. Hassing L.B., Johansson B., Nilsson S.E., et al. Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr 2002, 14(3):239-248.
37. MacKnight C., Rockwood K., Awalt E., et al. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 2002, 14(2):77-83.
38. Beeri M.S., Schmeidler J., Silverman J.M., et al. Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology 2008, 71(10):750-757.
39. Kalaria R.N. Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease. Nat Rev Neurol 2009, 5(6):305-306.
40. Wu J.H., Haan M.N., Liang J., et al. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: a population-based cohort study. Ann Epidemiol 2003, 13(5):369-376.
41. Banks W.A., Owen J.B., Erickson M.A. Insulin in the brain: there and back again. Pharmacol Ther 2012, 136(1):82-93.
42. Cholerton B., Baker L.D., Craft S. Insulin resistance and pathological brain ageing. Diabet Med 2011, 28(12):1463-1475.
43. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alzheimer Dis Assoc Disord 2006, 20(4):298-301.
44. White M.F. Insulin signaling in health and disease. Science 2003, 302(5651):1710-1711.
45. Baura G.D., Foster D.M., Kaiyala K., et al. Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs. Diabetes 1996, 45(1):86-90.
46. Benedict C., Brooks S.J., Kullberg J., et al. Impaired insulin sensitivity as indexed by the HOMA score is associated with deficits in verbal fluency and temporal lobe gray matter volume in the elderly. Diabetes Care 2012, 35(3):488-494.
47. Baker L.D., Cross D.J., Minoshima S., et al. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol 2011, 68(1):51-57.
48. Park C.R., Seeley R.J., Craft S., et al. Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 2000, 68(4):509-514.
49. Craft S., Asthana S., Cook D.G., et al. Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 2003, 28(6):809-822.
50. Reger M.A., Watson G.S., Green P.S., et al. Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. JAlzheimers Dis 2008, 13(3):323-331.
51. Reger M.A., Watson G.S., Green P.S., et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008, 70(6):440-448.
52. Craft S., Baker L.D., Montine T.J., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 2012, 69(1):29-38.
53. Claxton A., Baker L.D., Wilkinson C.W., et al. Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease. JAlzheimers Dis 2013, 35(4):789-797.
54. Cholerton B., Baker L.D., Trittschuh E.H., et al. Insulin and sex interactions in older adults with mild cognitive impairment. JAlzheimers Dis 2012, 31(2):401-410.
55. Braak H., Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997, 18(4):351-357.
56. Craft S., Cholerton B., Baker L.D. Insulin and Alzheimer's disease: untangling the web. JAlzheimers Dis 2013, 33(Suppl 1):S263-S275.
57. Watson G.S., Peskind E.R., Asthana S., et al. Insulin increases CSF Abeta42 levels in normal older adults. Neurology 2003, 60(12):1899-1903.
58. Boyt A.A., Taddei T.K., Hallmayer J., et al. The effect of insulin and glucose on the plasma concentration of Alzheimer's amyloid precursor protein. Neuroscience 2000, 95(3):727-734.
59. Craft S., Asthana S., Schellenberg G., et al. Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci 2000, 903:222-228.
60. Rogers J., Shen Y. Aperspective on inflammation in Alzheimer's disease. Ann N Y Acad Sci 2000, 924:132-135.
61. Dandona P. Endothelium, inflammation, and diabetes. Curr Diab Rep 2002, 2(4):311-315.
62. Krogh-Madsen R., Plomgaard P., Keller P., et al. Insulin stimulates interleukin-6 and tumor necrosis factor-alpha gene expression in human subcutaneous adipose tissue. Am J Physiol Endocrinol Metab 2004, 286(2):E234-E238.
63. Fishel M.A., Watson G.S., Montine T.J., et al. Hyperinsulinemia provokes synchronous increases in central inflammation and beta-amyloid in normal adults. Arch Neurol 2005, 62(10):1539-1544.
64. Olefsky J.M. Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. JClin Invest 2000, 106(4):467-472.
65. Combs C.K., Johnson D.E., Karlo J.C., et al. Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. JNeurosci 2000, 20(2):558-567.
66. Lehmann J.M., Lenhard J.M., Oliver B.B., et al. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. JBiol Chem 1997, 272(6):3406-3410.
67. Lim G.P., Yang F., Chu T., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. JNeurosci 2000, 20(15):5709-5714.
68. Rodriguez-Rivera J., Denner L., Dineley K.T. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral gluco-regulatory status. Behav Brain Res 2011, 216(1):255-261.
69. Pedersen W.A., McMillan P.J., Kulstad J.J., et al. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006, 199(2):265-273.
70. O'Reilly J.A., Lynch M. Rosiglitazone improves spatial memory and decreases insoluble Abeta(1-42) in APP/PS1 mice. JNeuroimmune Pharmacol 2012, 7(1):140-144.
71. Escribano L., Simon A.M., Gimeno E., et al. Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology. Neuropsychopharmacology 2010, 35(7):1593-1604.
72. Nicolakakis N., Aboulkassim T., Ongali B., et al. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. JNeurosci 2008, 28(37):9287-9296.
73. Searcy J.L., Phelps J.T., Pancani T., et al. Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. JAlzheimers Dis 2012, 30(4):943-961.
74. Watson G.S., Cholerton B.A., Reger M.A., et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005, 13(11):950-958.
75. Risner M.E., Saunders A.M., Altman J.F., et al. Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 2006, 6(4):246-254.
76. Gold M., Alderton C., Zvartau-Hind M., et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010, 30(2):131-146.
77. Harrington C., Sawchak S., Chiang C., et al. Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies. Curr Alzheimer Res 2011, 8(5):592-606.
78. Hanyu H., Sato T., Kiuchi A., et al. Pioglitazone improved cognition in a pilot study on patients with Alzheimer's disease and mild cognitive impairment with diabetes mellitus. JAm Geriatr Soc 2009, 57(1):177-179.
79. Sato T., Hanyu H., Hirao K., et al. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 2011, 32(9):1626-1633.
80. Geldmacher D.S., Fritsch T., McClendon M.J., et al. Arandomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch Neurol 2011, 68(1):45-50.
81. Sheu W.H., Chuang H.C., Cheng S.M., et al. Microdialysis combined blood sampling technique for the determination of rosiglitazone and glucose in brain and blood of gerbils subjected to cerebral ischemia. JPharm Biomed Anal 2011, 54(4):759-764.
82. Strum J.C., Shehee R., Virley D., et al. Rosiglitazone induces mitochondrial biogenesis in mouse brain. JAlzheimers Dis 2007, 11(1):45-51.
83. Festuccia W.T., Oztezcan S., Laplante M., et al. Peroxisome proliferator-activated receptor-gamma-mediated positive energy balance in the rat is associated with reduced sympathetic drive to adipose tissues and thyroid status. Endocrinology 2008, 149(5):2121-2130.
84. Grommes C., Karlo J.C., Caprariello A., et al. The PPARgamma agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. Cancer Chemother Pharmacol 2013, 71(4):929-936.
85. Maeshiba Y., Kiyota Y., Yamashita K., et al. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneimittelforschung 1997, 47(1):29-35.
86. Mannucci E., Monami M., Di Bari M., et al. Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2010, 143(2):135-140.
87. Holscher C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam Horm 2010, 84:331-354.
88. Green B.D., Gault V.A., Flatt P.R., et al. Comparative effects of GLP-1 and GIP on cAMP production, insulin secretion, and invivo antidiabetic actions following substitution of Ala8/Ala2 with 2-aminobutyric acid. Arch Biochem Biophys 2004, 428(2):136-143.
89. Sivertsen J., Rosenmeier J., Holst J.J., et al. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012, 9(4):209-222.
90. Gejl M., Egefjord L., Lerche S., et al. Glucagon-like peptide-1 decreases intracerebral glucose content by activating hexokinase and changing glucose clearance during hyperglycemia. JCereb Blood Flow Metab 2012, 32(12):2146-2152.
91. Bomfim T.R., Forny-Germano L., Sathler L.B., et al. An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease- associated Abeta oligomers. JClin Invest 2012, 122(4):1339-1353.
92. Bailey C.J., Turner R.C. Metformin. NEngl J Med 1996, 334(9):574-579.
93. Tian J., Shi J., Bailey K., et al. Association between apolipoprotein E e4 allele and arteriosclerosis, cerebral amyloid angiopathy, and cerebral white matter damage in Alzheimer's disease. JNeurol Neurosurg Psychiatry 2004, 75(5):696-699.
94. Labuzek K., Suchy D., Gabryel B., et al. Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep 2010, 62(5):956-965.
95. Kitabchi A.E., Temprosa M., Knowler W.C., et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 2005, 54(8):2404-2414.
96. Gupta A., Bisht B., Dey C.S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011, 60(6):910-920.
97. Chen Y., Zhou K., Wang R., et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA 2009, 106(10):3907-3912.
98. Kickstein E., Krauss S., Thornhill P., et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA 2010, 107(50):21830-21835.
99. Li J., Deng J., Sheng W., et al. Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice. Pharmacol Biochem Behav 2012, 101(4):564-574.
100. Bhutada P., Mundhada Y., Bansod K., et al. Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. Behav Brain Res 2011, 220(1):30-41.
101. Pintana H., Apaijai N., Pratchayasakul W., et al. Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci 2012, 91(11-12):409-414.
102. Abbatecola A.M., Lattanzio F., Molinari A.M., et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 2010, 33(8):1706-1711.
103. Imfeld P., Bodmer M., Jick S.S., et al. Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. JAm Geriatr Soc 2012, 60(5):916-921.
104. Hsu C.C., Wahlqvist M.L., Lee M.S., et al. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. JAlzheimers Dis 2011, 24(3):485-493.